EGRX - Eagle Pharma wins FDA approval for generic vasopressin

Eagle Pharmaceuticals (EGRX +13.1%) announced that the FDA has approved its abbreviated new drug application (“ANDA”) for vasopressin. The regulatory nod for the therapeutic equivalent of Vasostrict follows the recent legal battle won by Eagle (NASDAQ:EGRX) over Par Pharmaceutical et. al. In its ruling, the U.S. District Court for the District of Delaware had determined that Eagle’s (EGRX) proposed vasopressin product did not infringe any of the patents asserted by the group against the company. “We are implementing our launch plans to bring vasopressin to market,” CEO Scott Tarriff noted, adding that the company expects a 180-day marketing exclusivity for the product.

For further details see:

Eagle Pharma wins FDA approval for generic vasopressin